AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7584299 — intervention group
Group type: COMPARATOR
Intervention: Recall of novel actions after one year delay
Number of subjects: 0
Study 7584299 — intervention group
Group type: COMPARATOR
Intervention: Control group performance
Number of subjects: 0
Study 2685654 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR 50/200 mg
Number of subjects: 20
Study 2685654 — intervention group
Group type: COMPARATOR
Intervention: Conventional carbidopa/levodopa 25/250 mg
Number of subjects: 20
Study 790125 — intervention group
Group type: EXPERIMENTAL
Intervention: Raubasine (90 mg daily for 1-2 weeks)
Number of subjects: 19
Study 790125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30911920 — intervention group
Group type: EXPERIMENTAL
Intervention: Early closure of temporary ileostomy (8–13 days)
Number of subjects: 112
Study 30911920 — intervention group
Group type: COMPARATOR
Intervention: Late closure of temporary ileostomy (> 12 weeks)
Number of subjects: 112
Study 30980892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pudilan extract-containing toothpaste
Number of subjects: 120
Study 30980892 — intervention group
Group type: COMPARATOR
Intervention: Pudilan toothpaste simulator (Control)
Number of subjects: 120
Study 27801990 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (administered for 4 weeks alongside standard IVIg treatment)
Number of subjects: 8
Study 27801990 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 25133710 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (1.8 g of protein·kg bw(‐1)·day(‐1))
Number of subjects: 18
Study 25133710 — intervention group
Group type: COMPARATOR
Intervention: Normal protein diet (0.85 g of protein·kg bw(‐1)·day(‐1))
Number of subjects: 18
Study 23925417 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) with two to three NRTIs
Number of subjects: 2220
Study 20821200 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCNL
Number of subjects: 54
Study 19350183 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser treatment, lesions treated twice weekly for 13 weeks, starting with 50 to 100 mJ/cm2 and increasing by 50 mJ/cm2 until erythema appeared, for a maximum of 25 sessions or until 100% repigmentation.
Number of subjects: 34
Study 19350183 — intervention group
Group type: COMPARATOR
Intervention: Untreated control patches
Number of subjects: 34
Study 17032095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) combined with medication tapering
Number of subjects: 61
Study 17032095 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonspecific therapy)
Number of subjects: 61
Study 14645937 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural cessation programme (four session treatment administered individually by a health educator, plus monthly brief phone calls until one year follow up)
Number of subjects: 261
Study 14645937 — intervention group
Group type: COMPARATOR
Intervention: Self help materials only (control group)
Number of subjects: 261
Study 10386471 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg s.c. monthly + Flutamide 250 mg t.i.d. + Placebo daily
Number of subjects: 0
Study 10386471 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg s.c. monthly + Finasteride 10 mg (2 x 5 mg daily) + Placebo t.i.d.
Number of subjects: 0
Study 10386471 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 10 mg (2 x 5 mg daily) + Flutamide 250 mg t.i.d.
Number of subjects: 0
Study 8697708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 10
Study 8697708 — intervention group
Group type: COMPARATOR
Intervention: Normal daily activities
Number of subjects: 10
Study 2038520 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (stationary bicycle ergometer) for 8 weeks, 3 sessions per week (35-40 minutes each)
Number of subjects: 14
Study 2038520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 14
Study 6784140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 6784140 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6784140 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline and Diazepam
Number of subjects: 0
Study 6784140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31839082 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 7.5 mg plus fentanyl 20 μg (Group F)
Number of subjects: 65
Study 31839082 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 10 mg (Group B)
Number of subjects: 65
Study 27849380 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin 5 mg/day plus dapagliflozin 10 mg/day
Number of subjects: 534
Study 27849380 — intervention group
Group type: COMPARATOR
Intervention: saxagliptin 5 mg/day plus placebo
Number of subjects: 534
Study 27849380 — intervention group
Group type: COMPARATOR
Intervention: dapagliflozin 10 mg/day plus placebo
Number of subjects: 534
Study 26343594 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone + Dextromethorphan (60 mg/day)
Number of subjects: 149
Study 26343594 — intervention group
Group type: COMPARATOR
Intervention: Risperidone + Placebo
Number of subjects: 149
Study 25099079 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (40,000 IU, 8 weekly infusions)
Number of subjects: 43
Study 25099079 — intervention group
Group type: COMPARATOR
Intervention: Saline (sodium chloride [NaCl], 0.9%)
Number of subjects: 43
Study 23173755 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Number of subjects: 40
Study 23173755 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 40
Study 20810740 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual stimulation training (20 sessions, each lasting 30 minutes)
Number of subjects: 20
Study 20810740 — intervention group
Group type: COMPARATOR
Intervention: Visual stimulation training (20 sessions, each lasting 30 minutes)
Number of subjects: 20
Study 18278305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 75 mg/kg
Number of subjects: 12
Study 18278305 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloral hydrate 50 mg/kg plus hydroxyzine 2.0 mg/kg
Number of subjects: 12
Study 18278305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16249417 — intervention group
Group type: COMPARATOR
Intervention: 30% fraction of inspired oxygen (FIO2)
Number of subjects: 300
Study 16249417 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% fraction of inspired oxygen (FIO2)
Number of subjects: 300
Study 16249417 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (both 30% and 80% FIO2)
Number of subjects: 300
Study 12177096 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose suramin (3.192 g/m²)
Number of subjects: 390
Study 12177096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose suramin (5.320 g/m²)
Number of subjects: 390
Study 12177096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose suramin (7.661 g/m²)
Number of subjects: 390
Study 10094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous heparin drip
Number of subjects: 18
Study 10094358 — intervention group
Group type: COMPARATOR
Intervention: No heparin
Number of subjects: 18
Study 10094358 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 18
Study 7769072 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture with autologous granulosa-lutein cells
Number of subjects: 0
Study 7769072 — intervention group
Group type: COMPARATOR
Intervention: Control (without co-culture)
Number of subjects: 0
Study 3174726 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) - 15,000 Anti X-activated Factor Units, daily subcutaneous injection for 7 days after operation
Number of subjects: 92
Study 3174726 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin - 5,000 International Units, 2 daily subcutaneous injections for 7 days after operation
Number of subjects: 92
Study 3174726 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 92
Study 3174726 — intervention group
Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 92
Study 31712711 — intervention group
Group type: EXPERIMENTAL
Intervention: Average Real Variability (ARV) measured by ambulatory BP monitoring
Number of subjects: 100
Study 31712711 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime systolic ARV
Number of subjects: 100
Study 31712711 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime diastolic ARV
Number of subjects: 100
Study 31712711 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study 31316148 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA group on day 1
Number of subjects: 50
Study 31316148 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA group on day 5
Number of subjects: 50
Study 31316148 — intervention group
Group type: COMPARATOR
Intervention: SGA and AGA groups on days 1 and 5
Number of subjects: 50
Study 29231319 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and triple puncture technique (group A)
Number of subjects: 36
Study 29231319 — intervention group
Group type: COMPARATOR
Intervention: Routine electroacupuncture (group B)
Number of subjects: 36
Study 25870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (bilateral needling at PC6, depth 7 mm, mean time 17 min during anaesthesia) plus usual care
Number of subjects: 282
Study 25870177 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 282
Study 23007486 — intervention group
Group type: EXPERIMENTAL
Intervention: Postactivation potentiation (PAP) intervention with 3 preceding countermovement jumps (CMJs)
Number of subjects: 16
Study 23007486 — intervention group
Group type: COMPARATOR
Intervention: Control group without countermovement jumps (CMJs)
Number of subjects: 16
Study 21531178 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program (Group 1)
Number of subjects: 110
Study 21531178 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (Group 2)
Number of subjects: 110
Study 18928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80 or 160 mg/d (fixed dose) during Period 1
Number of subjects: 63
Study 18928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone flexible doses (20-160 mg/d) during Period 2
Number of subjects: 63
Study 18928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerability of ziprasidone
Number of subjects: 63
Study 18928413 — intervention group
Group type: EXPERIMENTAL
Intervention: QTcF intervals monitoring
Number of subjects: 63
Study 21775917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 6% 130/0.4 for 8 days
Number of subjects: 41
Study 21775917 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (RL) solution without colloid
Number of subjects: 41
Study 16150196 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi mixture (SQM) combined with microwave coagulation
Number of subjects: 72
Study 16150196 — intervention group
Group type: COMPARATOR
Intervention: Microwave coagulation (Control group)
Number of subjects: 72
Study 11827089 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural similarity in analogical problem solving
Number of subjects: 0
Study 11827089 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural similarity
Number of subjects: 0
Study 9868725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sai‐boku‐to
Number of subjects: 200
Study 9868725 — intervention group
Group type: COMPARATOR
Intervention: Antianxiety drug (diazepam) with vitamin B complex
Number of subjects: 200
Study 7979299 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of oral diethyldithiocarbamate (DTC) per m2 weekly for 12 weeks
Number of subjects: 19
Study 7979299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3187472 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5‐7.5 mg i.m., weight related)
Number of subjects: 60
Study 3187472 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodonum (15 mg i.m.)
Number of subjects: 60
Study 11212077 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicocelectomy (surgical intervention)
Number of subjects: 385
Study 11212077 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic occlusion of the spermatic vein
Number of subjects: 385
Study 11212077 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled studies on varicocelectomy
Number of subjects: 385
Study 31676658 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation programme delivered by trained staff
Number of subjects: 666
Study 31676658 — intervention group
Group type: COMPARATOR
Intervention: Internet-based training about depression recognition and management
Number of subjects: 666
Study 29161911 — intervention group
Group type: EXPERIMENTAL
Intervention: Naikan therapy
Number of subjects: 92
Study 29161911 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 92
Study 27189614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 71
Study 27189614 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation/support (PES)
Number of subjects: 71
Study 25256070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 102
Study 25256070 — intervention group
Group type: COMPARATOR
Intervention: Control (no ramipril)
Number of subjects: 102
Study 22305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenting area
Number of subjects: 610
Study 22305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial size
Number of subjects: 610
Study 22305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaptation depth
Number of subjects: 610
Study 22305962 — intervention group
Group type: EXPERIMENTAL
Intervention: Annular dilatation
Number of subjects: 610
Study 19914557 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) on management of STS
Number of subjects: 12000
Study 19914557 — intervention group
Group type: EXPERIMENTAL
Intervention: Seminal trials from the 1980s and 1990s
Number of subjects: 12000
Study 18091483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan artificial disc replacement
Number of subjects: 99
Study 18091483 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical fusion
Number of subjects: 99
Study 14998945 — intervention group
Group type: EXPERIMENTAL
Intervention: Coasting (withholding gonadotrophins)
Number of subjects: 48
Study 14998945 — intervention group
Group type: COMPARATOR
Intervention: Control (optimally responding women)
Number of subjects: 48
Study 11667990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer‐Lactate solution
Number of subjects: 0
Study 11667990 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 0
Study 9432077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime for 1 day
Number of subjects: 750
Study 9432077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study 8209072 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via metered dose inhaler (MDI)
Number of subjects: 15
Study 8209072 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via nebulizer
Number of subjects: 15
Study 2733581 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of endurance exercise training
Number of subjects: 22
Study 2733581 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 10)
Number of subjects: 22
Study 29956411 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM) with a painful cuff pressure at 70% of pressure-pain tolerance threshold (PTT)
Number of subjects: 20
Study 29956411 — intervention group
Group type: COMPARATOR
Intervention: Control session without conditioning
Number of subjects: 20
Study 29956411 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Number of subjects: 20
Study 28821512 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit vessel only PCI with potentially subsequent staged revascularisation
Number of subjects: 0
Study 28821512 — intervention group
Group type: COMPARATOR
Intervention: Immediate multivessel PCI
Number of subjects: 0
Study 26303741 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 132
Study 26303741 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 132
Study 26303741 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acupuncture
Number of subjects: 132
Study 26303741 — intervention group
Group type: COMPARATOR
Intervention: Medicine control
Number of subjects: 132
Study 23544680 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 placebo‐tailored booklets
Number of subjects: 424
Study 23544680 — intervention group
Group type: COMPARATOR
Intervention: 4 standard booklets
Number of subjects: 424
Study 21214610 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-101 (80 μg/kg)
Number of subjects: 23
Study 21214610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17368829 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social reactions
Number of subjects: 93
Study 17368829 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative social reactions
Number of subjects: 93
Study 17368829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral social reactions
Number of subjects: 93
Study 17368829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 93
Study 16959410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 39
Study 16959410 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 39
Study 16959410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12504052 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 Gy
Number of subjects: 43
Study 12504052 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 Gy
Number of subjects: 43
Study 12504052 — intervention group
Group type: COMPARATOR
Intervention: Control group (2.4 Gy)
Number of subjects: 43
Study 12504052 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 Gy)
Number of subjects: 43
Study 10371375 — intervention group
Group type: EXPERIMENTAL
Intervention: DD genotype
Number of subjects: 289
Study 10371375 — intervention group
Group type: COMPARATOR
Intervention: II and ID genotypes
Number of subjects: 289
Study 8848773 — intervention group
Group type: EXPERIMENTAL
Intervention: DEXA
Number of subjects: 18
Study 8848773 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA
Number of subjects: 18
Study 8848773 — intervention group
Group type: EXPERIMENTAL
Intervention: V urea
Number of subjects: 18
Study 8848773 — intervention group
Group type: COMPARATOR
Intervention: Gravimetric weight
Number of subjects: 18
Study 2072836 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-min walk at 60% VO2max
Number of subjects: 12
Study 2072836 — intervention group
Group type: COMPARATOR
Intervention: rest in a seated position
Number of subjects: 12
Study 6356177 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg haloperidol tablets (average 4.0 tablets, 20.0 mg/day)
Number of subjects: 41
Study 6356177 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg haloperidol tablets (average 3.9 tablets, 58.0 mg/day)
Number of subjects: 41
Study 6356177 — intervention group
Group type: COMPARATOR
Intervention: Higher oral haloperidol doses
Number of subjects: 41
Study 31676259 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (hypohydrated)
Number of subjects: 16
Study 31676259 — intervention group
Group type: COMPARATOR
Intervention: EUHY (euhydrated)
Number of subjects: 16
Study 28183347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital administration of thawed plasma
Number of subjects: 0
Study 28183347 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of ICS principles
Number of subjects: 0
Study 28183347 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliarity of clinicians with ICS culture
Number of subjects: 0
Study 28183347 — intervention group
Group type: COMPARATOR
Intervention: Conflicting resource allocation priorities
Number of subjects: 0
Study 28183347 — intervention group
Group type: COMPARATOR
Intervention: Communication bottlenecks
Number of subjects: 0
Study 27098548 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous interscalene blockade
Number of subjects: 120
Study 27098548 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supraclavicular blockade
Number of subjects: 120
Study 27098548 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 120
Study 24428334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-dependent patients (AP)
Number of subjects: 125
Study 24428334 — intervention group
Group type: COMPARATOR
Intervention: Control patients (CP)
Number of subjects: 125
Study 24428334 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-related interpretation bias
Number of subjects: 125
Study 22024668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the morning
Number of subjects: 42
Study 22024668 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/day (force-titrated to 10 mg/day after 1 week) in the evening
Number of subjects: 42
Study 22024668 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the morning
Number of subjects: 42
Study 22024668 — intervention group
Group type: COMPARATOR
Intervention: Placebo in the evening
Number of subjects: 42
Study 19503772 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal laser treatment
Number of subjects: 0
Study 19503772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of steroids
Number of subjects: 0
Study 19503772 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF)
Number of subjects: 0
Study 19503772 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 17244293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash and Counseling (treatment group)
Number of subjects: 0